



BARCODE

Person Completing Form / [Add translation in local language] Contact (phone or e-mail) / [Add translation in local language] Date (DD/MM/YYYY) / [Add translation in local language]

[Input fields for Person Completing Form, Contact, and Date]

PHYSICIAN INFORMATION / [ADD TRANSLATION IN LOCAL LANGUAGE]

Institution/Practice / [Add translation in local language]
 First Name / [Add translation in local language]
 Last Name / [Add translation in local language]
 Telephone Number (country code & number) / [Add translation in local language]
 E-mail Address (for report access) / [Add translation in local language]

Address (street name, no., city, postal code, country) / [Add translation in local language]
 Stamp (if necessary) / [Add translation in local language]

PATIENT INFORMATION / [ADD TRANSLATION IN LOCAL LANGUAGE]

First Name / [Add translation in local language]
 Last Name / [Add translation in local language]
 Date of Birth (DD/MM/YYYY) / [Add translation in local language] Personal Identification No. / [Add translation in local language]
 Gender (male/female/other - specify karyotype) / [Add translation in local language]

Address (street name, no., city, postal code, country) / [Add translation in local language]
 Telephone Number (country code & number) / [Add translation in local language]
 Reason for Test (diagnosis, predictive, carrier) / [Add translation in local language]
 Sample Collection Date (DD/MM/YYYY) / [Add translation in local language]

DECLARATION OF CONSENT (ACCORDING TO GERMAN GENETIC DIAGNOSTICS ACT, GenDG)

APPLICABLE only for the determination of genetic (hereditary) characteristics

The GenDG requires provision of detailed information and a written consent for all genetic investigations as well as genetic counselling prior to both predictive (applies to healthy individuals) and prenatal testing (with restrictions: prenatal testing is not performed for late manifesting disorders, including Hereditary Cancer Panels). The German Society of Human Genetics (GfH) and the Association of German Human Geneticists (BVDH) recommend clarifying the issues listed below during the information process. Please read the declaration of consent carefully and tick the boxes, in accordance with your consent.

By signing the form below I confirm that I:

- Have been fully informed by my physician about the significance and consequences of the genetic investigation, in compliance with GenDG.
- Have read/have been read the Informed Consent which is attached to this form and which I fully understand.
- Have been given sufficient opportunity to discuss open questions.
- Authorize [insert legal entity here] to collect the necessary samples for investigation (blood, tissue, chorionic villus cells or amniotic fluid for prenatal diagnosis) and to send this form to MVZ Martinsried GmbH, Lochhamer Str. 29, 82152 Martinsried, Germany, in order to perform the tests requested through this form.
- Consent to the genetic test being carried out in order to clarify the disease/dysfunction/suspected diagnosis below.

In addition,

- I agree that a copy of the results of the analysis may be sent to the following physician(s), in accordance with my express requests and according to [insert legal entity here] internal procedures. YES NO

Dr(s) Name [Input field]
 Street [Input field]
 Postcode/City [Input field]
 Country [Input field]
 Place [Input field]
 Signature of Parent or Legal Guardian [Input field]

- I agree that the investigation or parts of the investigation may be forwarded to collaborating medical laboratories, if necessary. YES NO
- I agree with the evaluation of additional genes in the same indication group as part of the research. YES NO
- I agree that the remaining specimens may be stored for further investigations after the examination is completed, yet not claiming storage. YES NO
- I agree that the specimens, and if applicable DNA sequence information, may be made available anonymously for quality management and scientific purposes. YES NO
- I agree that the results of the analysis may be stored for a longer period than the statutory period of 10 years, yet not claiming storage of results. YES NO
- I agree to the storage and use of my test results under the protection of anonymity in a statistical database used for scientific purposes and to help diagnose genetic diseases. I understand that I will remain under the protection of anonymity and I cannot be identified during the analysis of the data and that any personal information will be transformed into information of a non-personal nature. YES NO

By signing the form below I confirm that:

- I may stop the investigation at any time and ask for the results available until that time to be destroyed.
- I may withdraw any of my consents given through this form entirely or in part at any time without giving reasons.
- I will be charged for the costs incurred until the time of withdrawal of consent.
- I may choose not to be informed about the test results (right not to know).
- The genetic investigation and evaluation is limited to the requested indication and no statements will be made about other diseases.
- All information I have provided is true and correct.

Communication of additional findings found during the course of the research

- Yes, I wish to be informed about additional findings.
 No, I do not wish to be informed about additional findings.

Date [Input field]
 Physician's Signature [Input field]

HISTOPATHOLOGY / [ADD TRANSLATION IN LOCAL LANGUAGE]

SAMPLE DETAILS

Specimen:	<input type="text"/>	Retrieved Date:	<input type="text"/>
Specimen ID:	<input type="text"/>	Collection Date:	<input type="text"/>
Block ID:	<input type="text"/>	Collection Time:	<input type="text"/>
Fixative/Preservative:	<input type="text"/>	Biopsy Details/Body Site:	<input type="text"/>

Reason for Referral:

New Diagnosis Relapse In Remission Monitoring Other

Relevant Clinical Information:

Comprehensive information regarding clinical history and diagnosis is essential for interpretation of genomic findings and drug therapy recommendations. Please attach patient's pathology report (if available), clinical history, and other applicable report(s).

If histopathology was conducted, please fill in:

Stage: Primary Metastasis – If Metastasis, list Primary:

0 I II III IIIA IIIB IV Note:

Slides # _____ Unstained _____ Stained _____ H&E _____

ICD-10 Code/Narrative:

Percentage of Tumor Cells:

Conclusion of the report, if any:

E.g., type of cancer, tumor grade, lymph node status, margin status, stage, whether the tumor has hormone receptors or other tumor markers

Our pathologists will recommend the most appropriate sequencing analysis, if necessary, and provide professional interpretation of the results.



BARCODE

MOLECULAR ANALYSIS / [ADD TRANSLATION IN LOCAL LANGUAGE]

Please choose the appropriate panel below to make your selection.

TARGETED-THERAPY TESTS

1 Bladder Cancer

IHC markers: CD44, CK20, CK7, GATA3, Ki67, p53
Genes: *FGFR2, FGFR3*

2 Breast Cancer

IHC markers: E-CD, ER, GATA3, HER2, Ki67, PR
Genes: *BRCA1, BRCA2, PIK3CA*
Molecular markers: fusion genes MSI

3 Colorectal Cancer

IHC markers: CDX-2, CK20, MLH1, MSH2, MSH6, PMS6, villin
Genes: *BRAF, KRAS, NRAS*
Molecular markers: fusion genes MSI

4 Gastric Cancer

IHC markers: CDX-2, CG-A, CK20, CK7, HER-2, Ki67, SYN
Molecular markers: fusion genes MSI

5 Gastrointestinal Stromal Tumor

IHC markers: CD34, c-KIT (CD117), desmin, DOG1, Ki67, S100
Genes: *BRAF, KIT, NF1, PDGFRA, SDHA*
Molecular markers: fusion genes

6 Melanoma

IHC markers: HMB45, Ki67, Melan-A, p16, S100, SOX10
Genes: *BRAF, KIT, NRAS*
Molecular markers: fusion genes

7 Non-Small Cell Lung Carcinoma

IHC markers: ALK, CG-A, EGFR, p40, PD-L1, ROS, SYN, TTF1
Genes: *BRAF, EGFR, ERBB2, KRAS, MET*
Molecular markers: fusion genes

8 Ovarian Cancer

IHC markers: AFP, calretinin, EMA, ER, hCG, inhibin, napsin A, OCT3/4, p16, p53, PAX8, PR, SALL4, WT1
Genes: *BRCA1, BRCA2*
Molecular markers: fusion genes MSI

9 Pancreatic Cancer

IHC markers: CK19, CK20, CK7, MUC5AC
Genes: *BRAF, BRCA1, BRCA2, KRAS, PALB2, SMAD4*
Molecular markers: fusion genes MSI

10 Prostate Cancer

IHC markers: BCC-AMACR, CK34BE12, CK5/6, NKX3.1, p63, PSA, PSAP
Genes: *ATM, BRCA1, BRCA2, CDK12, CHEK2, FANCA, PALB2, PTEN, RAD51*
Molecular markers: MSI

Fusion genes: ALK, NTRK, RET, ROS; IHC, immunohistochemistry; MSI, microsatellite instability

SOLID TUMOR PANELS (AND FUSION GENES)

Bladder Cancer

- 11 Gene Panel
- 11 Fusion Genes

Breast Cancer

- 12 Gene Panel

Colorectal Cancer

- 13 Gene Panel

Gastric Cancer

- 14 Gene Panel

Gastrointestinal Stromal Tumor

- 15 Gene Panel

Glioblastoma

- 16 Gene Panel

Liver Cancer

- 17 Fusion Genes

Lung Cancer

- 18 Fusion Genes

Melanoma

- 19 Gene Panel

Non-Small Cell Lung Carcinoma

- 20 Gene Panel
- 20 Fusion Genes

Ovarian Cancer

- 21 Gene Panel

Pancreatic Cancer

- 22 Gene Panel
- 22 Fusion Genes

Prostate Cancer

- 23 Gene Panel
- 23 Fusion Genes

Salivary Gland Sarcoma

- 24 Fusion Genes

Soft Tissue Sarcoma

- 25 Fusion Genes

Thyroid Cancer

- 26 Gene Panel
- 26 Fusion Genes

27 COMPREHENSIVE SOLID TUMOR PANEL

Please note that other gene fusions in addition to those specified may be detected by this assay and will be reported if they are of potential clinical significance.

For our complete gene list, turnaround times, specimen requirements and more, please visit our website: www.medicover-genetics.com.



PATIENT INFORMATION / [ADD TRANSLATION IN LOCAL LANGUAGE]

First Name / [Add translation in local language]

Last Name / [Add translation in local language]

Date of Birth (DD/MM/YYYY) / [Add translation in local language]

Gender (male/female/other - specify karyotype) / [Add translation in local language]

Telephone Number (country code & number) / [Add translation in local language]

E-mail Address / [Add translation in local language]

Clinical Diagnosis / [Add translation in local language]

Genetic counselling or counselling by the ordering physician is necessary before ordering a test in order to inform the patient of all of the possible outcomes and the limitations of the genetic test.

I understand that I will be tested for:

(To be filled in by physician)

I understand that the biological sample will be used to determine if I, or members of my family, are carriers of a genetic variant causing the disease, or are carriers of the disease, or have an increased risk of developing a disease.

The role of genetic testing. In many cases, a genetic test can directly detect a genetic alteration. Molecular tests can identify structural changes in the DNA (variants). Cytogenetic tests identify the chromosomal changes (structural or numerical). The sensitivity and specificity of each test varies.

The tests offered are complex analyses and are performed using high-end equipment. The methods are externally validated, but there is a minimal possibility of errors.

The significance of the results. If the result is identified as being directly causative of the clinical manifestations, it is considered to be **conclusive**. If the test does not identify the causative mutations of the clinical manifestations, it is considered to be **inconclusive** and this does not preclude other genetic changes (or non-genetic factors) responsible for the disease (a genetic disease or susceptibility to a genetic condition is not excluded). Therefore, an inconclusive result (no causative mutation identified) does not exclude the existence of other pathogenic genetic changes (variants) not tested through the current analysis.

Interpretation of the genetic results relies on a **complete clinical picture of the patient**, including clinical manifestations, family medical history and previous diagnoses. An error in diagnosis could occur due to a clinical picture that is different from that declared. In addition, the test can identify a possible nonpaternity. The test results will be forwarded to the patient by the geneticist or ordering physician and are **confidential**.

Incidental findings. Genetic testing can provide information unrelated to the purpose of the test, but that may have medical importance for the patient or family (information correlated with an increased risk for incurable disorders).

Use of the sample/result. The sample provided will be used solely for the purpose of the test and for which I have given my written consent.

Test results can also be used for research and to improve the diagnosis and treatment of genetic diseases.

The genetic material can be used for other purposes only with my prior express written consent.

Post-testing genetic counselling. A conclusive result may offer the patient information on the susceptibility, diagnosis, possible prognosis and/or heritability of the disease. An inconclusive result may lead to confusion and anxiety or may suggest the need for further genetic testing. Therefore, post-testing genetic counselling is advised for the clinical interpretation of the results.

By my signature, I hereby certify that:

1. I have been informed of the nature and purpose of the genetic test.
2. I have been informed of the benefits and limitations of the genetic test by (name of physician).
3. I have been informed that the genetic test can provide information/results which have no connection with the purpose of testing. I understand that only I decide if I want those additional results to be provided.
4. I have received clear answers to my questions in relation to the genetic test.
5. I have received a copy of this form.
6. I agree to provide a sample for the above mentioned genetic test.

I have explained the risks and benefits of the test as well as alternative test methods to the patient or parent/legal guardian. I have answered all the questions from the patient or parent/legal guardian.

Name of the ordering physician

First Name

Signature of the Ordering Physician

Completed by: Parent/Legal Guardian Patient

First Name

Last Name

Date of Completion

Signature

Last Name

Date of Signature